Medix Biochemica has acquired 100 percent of the shares of Bioresource Technology (BRT) to broaden its base matrix capabilities and further strengthen its local presence in the US market. As a result of this partnership, Medix Biochemica will provide its customers with a comprehensive offering of raw materials for their IVD quality control products. The […]
Ixaka, an integrated cell and gene therapy company, and Minaris Regenerative Medicine, a leading contract development and manufacturing service provider for the cell and gene therapy industry, have signed an agreement to enable technology transfer as well as clinical and commercial manufacture of REX-001, Ixaka’s lead autologous multi-cell therapy (MCT) being developed for the treatment […]
Cardiovascular DX company CardiNor AS has signed an exclusive agreement with IBL-America for sales of the CardiNor Secretoneurin ELISA test in the US. By initially targeting research institutes, clinical research organisations and pharmaceutical companies, CardiNor aims to spread awareness of this important new frontline biomarker and pave the way for future commercialisation upon US regulatory […]
Fujifilm is at the forefront of the digital histopathology revolution, centred around the Dynamyx software by Inspirata, and supported by partnerships that drive improvements in patient care.
The Olympus Provi CM20 incubation monitoring system has won the prestigious “Best of the Best” award in the Product Design category of the 2022 Red Dot Design Award. This Award is bestowed on a product that the Red Dot Jury deems as groundbreaking and is the highest honour given in this world-renowned design competition.
ProteoNic, a leading provider of premium vector technology and services for production of biologics, and FyoniBio, a contract development organization for biopharmaceuticals, have entered into a technology licensing agreement. Under the agreement, FyoniBio gains worldwide, non-exclusive commercial rights for application of ProteoNic techno-logy in its proprietary CHOnamite platform. As a result, FyoniBio’s clients will profit […]
The digital information services on offer at this year’s MEDICA & COMPAMED – to be held November 14-17 in Düsseldorf, Germany – will enable visitors to prepare in advance for meetings with exhibitors.
The exhibitor profile is at the heart of the exhibiting companies’ digital trade fair presence, and is thus an important tool for companies that want to be found by customers, both digitally and on-site. The relaunch of the exhibitor profiles was rolled out from the middle of July across all Messe Düsseldorf online portals.
“Companies need to present themselves and their products to their best advantage, both live at the trade fair and online. The new exhibitor profile enables them to do this,” explained Wolfram N. Diener, CEO of Messe Düsseldorf. “We have reinvested in platforms that we can provide to our customers both in-person and digitally. Our trade fairs are open 365 days a year on our online portals. They form the first point of contact for their relevant sectors. In order to provide our customers with the greatest level of benefit, we maintain a regular exchange and continue the development our digital services, such as the online portals.”
The revamped exhibitor profile has a modern, clean design and has been further optimised for mobile devices. Users can filter the offers listed there according to their personal interests. This means that companies, their products, trade fair events and company news can be found simply and quickly. It is also easier to contact companies and create personalised favourite lists at the click of a button, enabling visitors to prepare for the trade fair with very little effort.
Digital discussion circles
The MEDICA DEEP DIVE digital discussion circles, held in English, have been conceived as a warm-up, so that content for trade fair participation can be prepped in a purposeful manner. They bring relevant, trending topics from the healthcare sector into focus. It starts on September 22, with “Diagnostics for infectious diseases”, in which current innovations and developments in point-of-care diagnostics are among the central topics. The topics of “Artificial Intelligence/big data in a medical setting” and “The smart hospital” follow soon afterwards. The moderated online discussion circles present cutting-edge expert knowledge from the industry, clinical practice and science in 45-minute segments and can be streamed on the industry portal, MEDICA Deep Dive.
Bookings increase
Looking at the trend for exhibitor bookings suggests that participation at MEDICA 2022 and at the parallel event COMPAMED 2022, the international leading trade fair for the supplier sector for the medical technology industry, will exceed the participation level at the events in 2021.
German Hospital Conference
Of several events on the programme at MEDICA, the 45th German Hospital Conference is the leading event for top management of German clinics. The programme also includes the DiMiMED Conference on Disaster and Military Medicine, and the MEDICA MEDICINE + SPORTS CONFERENCE.
New HEPA filters keep air clean
Along with well-developed programme planning, technical equipment also ensures the best conditions for MEDICA 2022 and COMPAMED 2022. In the first half of 2022, the entire Düsseldorf trade fair and congress centre was fitted with HEPA filters. These are currently the most effective form of air treatment technology and are also used in operating theatres and intensive care wards. HEPA filters remove 99.9% of the viruses, bacteria and other particles from the air. The purified air is then fed back into the room.
“In combination with high-performance air conditioning systems, the filters in our huge halls ensure that our guests can attend the trade fair with a sense of security.” explained Christian Grosser, Director Healthcare & Medical Technologies of Messe Düsseldorf.
FUJIFILM Irvine Scientific, a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, has more than doubled their R&D facility’s footprint with the recent completion of its Armstrong Cell Culture Center of Excellence. The new state-of-the-art centre enables the company to expand its capabilities in cutting-edge discovery research, bioproduction, cell and gene therapy, Assisted Reproductive Technologies (ART) and cytogenetics.
Based at FUJIFILM Irvine Scientific’s headquarters in Santa Ana, California, the facility has now been opened to its growing Life Sciences and Medical Media divisions. Having experienced significant growth in recent years, the company continues to invest in new facilities globally, including opening new sites in Europe and Asia within the past year.
The new Armstrong Center will support many of its new programmes and initiatives, including Manufacturing Sciences and Technologies (MSAT), Single-Use technology development, and automation platforms for media development. Alongside this, the expanded facility will offer dedicated workspace for cutting-edge research into analytical chemistry, virology, ART and additional cell culture and molecular-based assay development, providing additional employment opportunities and projecting a doubling of growth in R&D headcount by the end of the year.
Bob Newman, Chief Scientific Officer, FUJIFILM Irvine Scientific, commented: “Continuing our 50 years’ of success and experience in the cell biology and cell culture solutions industry, we are driving forward with expansion plans to support ongoing innovation and growth across our diverse offerings of specialty media, technologies, and custom media services.
“The global demand for access to these high quality and cost-effective therapies and services is increasing faster than ever before. Through this new Californian site, as well as the recent opening of the Collaboration and Innovation Center in Suzhou New District, China, FUJIFILM Irvine Scientific is poised to provide enhanced technical collaboration opportunities between R&D experts worldwide, supporting development of personalized solutions and partnership opportunities.”
Suzanne Foster, new president of Beckman Coulter Life Sciences
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, has appointed Suzanne Foster as President of the company.
Foster joins Beckman Coulter Life Sciences from Cardinal Health, where she spent the past two years serving as President of the Health-at-Home business. A seasoned executive, Foster brings more than 25 years of experience in the healthcare industry.
She has previously served as President of Healthcare at Stanley Black & Decker, where her leadership style and commitment to innovation substantially grew the business. Her robust career also includes ten years at Medtronic as General Manager of their Advanced Energy business.
“The legacy and mission of Beckman Coulter Life Sciences, along with the commitment to customers and innovation resonated with me long ago,” Foster said. “As I meet with customers, I hear firsthand how important it is for us to continue developing automation solutions to help labs increase speed, reduce errors, and deliver advanced analytics. We will continue our relentless pursuit to be the trusted and preferred partner to help labs answer important scientific questions and overcome healthcare challenges.”
Foster holds an MPH in Law and Health Policy from Harvard University, a J.D. from Suffolk University, an M.Ed. in Psychology from Notre Dame College, and a B.A. in Communication from the University of New Hampshire.
Her passion for helping others took root when she started her career as a clinical social worker for an in- patient psychiatric unit. With a mission to drive meaningful change, Foster went on to law school and practiced health law before she moved into chief operating roles.
“At every level, I’ve seen the need for efficient and timely testing and research solutions,” Foster said. “We will continue to lead the way with pioneering new technologies that can help laboratories of all sizes achieve these goals and bring down costs. It excites me to know that our instruments are helping labs around the world with their next big breakthrough and improving the lives of patients, while easing the manual workload on staff.”
Foster succeeds Greg Milosevich, who has taken a new position in the life sciences companies of Danaher Corporation, of which Beckman Coulter Life Sciences is also a member.
Headquartered in Indianapolis, Indiana, Beckman Coulter Life Sciences has a substantial global footprint which includes 11 large operational facilities, more than 3,300 associates, and more than 300,000 Beckman Coulter Life Sciences systems installed globally.
Beckman Coulter, a global leader in clinical diagnostics, and Scopio Labs, a MedTech company that develops AI-powered workflow solutions, have established a worldwide partnership to accelerate adoption of Scopio’s next generation peripheral blood smear platforms.
Scopio’s technology employs Full-Field imaging and AI decision support to truly eliminate manual microscopy, while providing laboratory professionals and clinicians a true workflow benefit. With simple to use remote viewing, the Scopio solutions simplify lab operations and improve workflow in a distributed network. High resolution full-field images can now be shared in real time over a secure hospital network – no more slides being shipped between locations.
“In today’s busy laboratory environment, manual operations are a strain on precious resources,” said Dr Peter Soltani, senior vice president & general manager at Beckman Coulter. “Scopio enables fast digital capture of a wide field of view of a smear, from the feathered edge to the monolayer. By leveraging computational photography, Scopio generates a high resolution, full-field image of the sample including a large scan area and the smallest details. This is a leap in digital morphology capabilities, and with easy and secure remote viewing, can help laboratories significantly reduce manual labour burden, while improving turnaround time. A powerful AI-driven decision support solution also speeds interpretation and reporting of results. We are excited to partner with Scopio Labs to bring cutting edge digital peripheral blood smear analysis and the use of AI decision support to our customers, continuing our push to innovate and solve everyday problems for the lab.”
Itai Hayut, CEO and cofounder of Scopio Labs, said: “As 70% of all medical decisions depend on laboratory test results , it’s crucial that diagnostic excellence and innovation are placed at the forefront of healthcare. It is an honour to partner with Beckman Coulter, the pioneers of automated haematology testing and a known industry innovator, to accelerate the digital transformation of haematology laboratories worldwide. By introducing digitalization to Peripheral Blood Smear review at scale, Scopio completes a crucial piece of the puzzle. This partnership is a vote of confidence in our Full-Field cell morphology imaging and AI-powered analysis platform as the market’s new standard – we’re moving away from snapshots of individual cells and into end-to-end digitalization.”
With the increasing worldwide attention of haematological disorders and malignancies, the accuracy and timeliness of Peripheral Blood Smear (PBS) results are critically important for early diagnosis and effective treatment initiation. The peripheral blood smear review is a powerful diagnostic tool that provides clinicians information about a variety of disorders such as blood related cancers, anaemia, infections and many other life-threatening medical conditions. The majority of these tests are performed manually, but Scopio’s disruptive ‘Full-Field Peripheral Blood Smear’ morphology solution completely eliminates the need for additional manual microscopic examination.
Tele-haematology
In manual microscopy, users must choose between a large field of view or high resolution. Scopio’s devices eliminate that tradeoff completely, capturing large scan areas at 100X magnification. Holding 30 slides and processing up to 40 samples an hour, Scopio’s X100HT can meet the high throughput requirements of large hospitals and labs, while fully supporting remote review capabilities, enabling a new subfield of tele-haematology. Hospital and lab networks can now operate seamlessly across multiple facilities of all sizes, with workload balancing, remote consultations, addressing personnel shortages and more.
In May, Scopio Labs received U.S. FDA clearance of its X100HT device with PBS Application coupling high throughput capabilities with high resolution scanning for haematological analysis. Catering to large medical facilities and labs across the world, the X100HT complements the previously cleared X100 instrument designed with a 3-slide tray and a throughput of up to 15 slides an hour for a 200 WBC Diff, making it an optimal solution for small to medium size laboratories.
July / August 2022
Parklaan 54a
5613 BH
Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.